Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | MIF | P14174 | 1/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13186559 | 0.84 | MIF (0.61) | RAB9ANPC1MIFGABRA1CYP1A2 | |
| SCHEMBL1001394 | 0.83 | MIF (0.60) | RAB9ANPC1MIFGABRA1CYP1A2 | |
| SCHEMBL3185812 | 0.81 | MIF (0.58) | RAB9ANPC1MIFGABRA1CYP1A2 | |
| SCHEMBL2958852 | 0.78 | MIF (0.71) | RAB9ANPC1MIFGABRA1CYP3A4 | |
| SCHEMBL30863871 | 0.78 | RAB9A (1.00) | RAB9ANPC1ALOX5CYP19A1AXL | |
| SCHEMBL221183 | 0.78 | RAB9A (1.00) | RAB9ANPC1ALOX5CYP19A1AXL | |
| SCHEMBL3183486 | 0.75 | ALDH1A1 (0.61) | RAB9ANPC1MIFGABRA1CYP1A2 | |
| SCHEMBL3198753 | 0.75 | GABRA1 (0.51) | RAB9ANPC1MIFGABRA1CYP19A1 | |
| SCHEMBL2961592 | 0.74 | MIF (0.62) | RAB9ANPC1MIFGABRA1MKNK1 | |
| SCHEMBL2962468 | 0.74 | MIF (0.51) | RAB9ANPC1MIFGABRA1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173360-B2 | Cell death inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173360-B2 | Cell death inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173360-B2 | Cell death inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-2270505-A1 | A method of screening a cell death inhibitor using macrophage migration inhibitory factor (MIF) | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| EP-2270505-A1 | A method of screening a cell death inhibitor using macrophage migration inhibitory factor (MIF) | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100099106-A1 | CELL DEATH INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099106-A1 | CELL DEATH INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099106-A1 | CELL DEATH INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
| US-7659267-B2 | 1,3-Benzothiazinone derivatives, process for producing the same use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20060052371-A1 | 1,3-Benzothiazinone derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20060034832-A1 | Cell death inhibitor | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 2006-02-16 | — | — | US | disclosed |
| EP-1568697-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1500402-A1 | CELL DEATH INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-6794383-B2 | Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-09-21 | — | — | US | disclosed |
| US-20030186971-A1 | Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1325918-A1 | HEART MUSCULAR CELL APOPTOSIS INHIBITORS AND REMEDIES/PREVENTIVES FOR HEART DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186971-A1 | Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases | TNNI3, TNNT2, BAX | RAB9A 3969/4885NPC1 2461/4885MIF 2269/4885 |
| US-20060034832-A1 | Cell death inhibitor | MIF, TNFSF11, PDCD6IP | RAB9A 3814/4885NPC1 1414/4885MIF 1/4885 |
| US-20060052371-A1 | 1,3-Benzothiazinone derivatives, process for producing the same and use thereof | MIF, FOXM1, HMGB3 | RAB9A 4089/4885NPC1 3291/4885MIF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.